Cargando…
Emerging Therapeutic Biomarkers in Endometrial Cancer
Although clinical trials of molecular therapies targeting critical biomarkers (mTOR, epidermal growth factor receptor/epidermal growth factor receptor 2, and vascular endothelial growth factor) in endometrial cancer show modest effects, there are still challenges that might remain regarding primary/...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693108/ https://www.ncbi.nlm.nih.gov/pubmed/23819113 http://dx.doi.org/10.1155/2013/130362 |
_version_ | 1782274706127192064 |
---|---|
author | Dong, Peixin Kaneuchi, Masanori Konno, Yosuke Watari, Hidemichi Sudo, Satoko Sakuragi, Noriaki |
author_facet | Dong, Peixin Kaneuchi, Masanori Konno, Yosuke Watari, Hidemichi Sudo, Satoko Sakuragi, Noriaki |
author_sort | Dong, Peixin |
collection | PubMed |
description | Although clinical trials of molecular therapies targeting critical biomarkers (mTOR, epidermal growth factor receptor/epidermal growth factor receptor 2, and vascular endothelial growth factor) in endometrial cancer show modest effects, there are still challenges that might remain regarding primary/acquired drug resistance and unexpected side effects on normal tissues. New studies that aim to target both genetic and epigenetic alterations (noncoding microRNA) underlying malignant properties of tumor cells and to specifically attack tumor cells using cell surface markers overexpressed in tumor tissue are emerging. More importantly, strategies that disrupt the cancer stem cell/epithelial-mesenchymal transition-dependent signals and reactivate antitumor immune responses would bring new hope for complete elimination of all cell compartments in endometrial cancer. We briefly review the current status of molecular therapies tested in clinical trials and mainly discuss the potential therapeutic candidates that are possibly used to develop more effective and specific therapies against endometrial cancer progression and metastasis. |
format | Online Article Text |
id | pubmed-3693108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-36931082013-07-01 Emerging Therapeutic Biomarkers in Endometrial Cancer Dong, Peixin Kaneuchi, Masanori Konno, Yosuke Watari, Hidemichi Sudo, Satoko Sakuragi, Noriaki Biomed Res Int Review Article Although clinical trials of molecular therapies targeting critical biomarkers (mTOR, epidermal growth factor receptor/epidermal growth factor receptor 2, and vascular endothelial growth factor) in endometrial cancer show modest effects, there are still challenges that might remain regarding primary/acquired drug resistance and unexpected side effects on normal tissues. New studies that aim to target both genetic and epigenetic alterations (noncoding microRNA) underlying malignant properties of tumor cells and to specifically attack tumor cells using cell surface markers overexpressed in tumor tissue are emerging. More importantly, strategies that disrupt the cancer stem cell/epithelial-mesenchymal transition-dependent signals and reactivate antitumor immune responses would bring new hope for complete elimination of all cell compartments in endometrial cancer. We briefly review the current status of molecular therapies tested in clinical trials and mainly discuss the potential therapeutic candidates that are possibly used to develop more effective and specific therapies against endometrial cancer progression and metastasis. Hindawi Publishing Corporation 2013 2013-06-11 /pmc/articles/PMC3693108/ /pubmed/23819113 http://dx.doi.org/10.1155/2013/130362 Text en Copyright © 2013 Peixin Dong et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Dong, Peixin Kaneuchi, Masanori Konno, Yosuke Watari, Hidemichi Sudo, Satoko Sakuragi, Noriaki Emerging Therapeutic Biomarkers in Endometrial Cancer |
title | Emerging Therapeutic Biomarkers in Endometrial Cancer |
title_full | Emerging Therapeutic Biomarkers in Endometrial Cancer |
title_fullStr | Emerging Therapeutic Biomarkers in Endometrial Cancer |
title_full_unstemmed | Emerging Therapeutic Biomarkers in Endometrial Cancer |
title_short | Emerging Therapeutic Biomarkers in Endometrial Cancer |
title_sort | emerging therapeutic biomarkers in endometrial cancer |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693108/ https://www.ncbi.nlm.nih.gov/pubmed/23819113 http://dx.doi.org/10.1155/2013/130362 |
work_keys_str_mv | AT dongpeixin emergingtherapeuticbiomarkersinendometrialcancer AT kaneuchimasanori emergingtherapeuticbiomarkersinendometrialcancer AT konnoyosuke emergingtherapeuticbiomarkersinendometrialcancer AT watarihidemichi emergingtherapeuticbiomarkersinendometrialcancer AT sudosatoko emergingtherapeuticbiomarkersinendometrialcancer AT sakuraginoriaki emergingtherapeuticbiomarkersinendometrialcancer |